This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Shire Pharmaceuticals Group PLC
Drug Names(s): NTCD (non-toxigenic Clostridium difficile), VP 20621, VP-20621
Description: NTCD contains the spores of a non-toxin producing strain of C. difficile. Colonization with this strain may prevent overgrowth of toxin-producing C. difficile.
ViroPharma and Shire
In November 2013, Shire and ViroPharma entered into a merger agreement pursuant to which Shire will acquire all of the outstanding shares of ViroPharma for $50 per share in cash, for a total consideration of approximately $4.2 billion.
In January 2014, Shire announced the successful completion of the tender offer for all of the outstanding shares of ViroPharma.
Abbvie and Shire
In July 2014, AbbVie and Shire announced that they have reached agreement on the terms of a recommended combination of Shire with AbbVie.
Additional information available to subscribers only: